Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 36 min ago
PreprintCC BY-NC-NDbioRxiv

Single-cell characterization of 3D CLL spheroid model that recapitulates lymph node microenvironment-driven phenotypes and in vivo drug responses to ibrutinib

  1. 1Amsterdam UMC

Abstract

Lymph node (LN) microenvironmental signals promote chronic lymphocytic leukemia (CLL) cell survival, proliferation, and treatment resistance. We previously developed a 3D culture model that recapitulates key features of this protective LN niche. Using single-cell RNA sequencing of ex vivo paired peripheral blood and LN samples, together with matched patient-derived CLL spheroids, we investigated how microenvironmental cues shape CLL phenotypes and their response to ibrutinib. A total of 3 functional CLL states (resting, activated, proliferating) were identified, with expanded populations of activated and proliferating subsets in 3D cultures. After 5 days of in vitro ibrutinib treatment, CLL cells shifted toward a resting phenotype, reflecting published responses in patients at 6 months. Activated CLL cells showed relative resistance to ibrutinib, associated with TLR9-MALT1-MYC pathway activation. The 3D model recapitulated tissue-specific T cell phenotypes observed in patients, and computational analyses predicted several T-to-CLL cell-mediated interactions supporting the LN niche. Collectively, these data reveal distinct ibrutinib responses among CLL subsets and establish the 3D model as a physiologically relevant platform.

Related

  1. Quantitative MRI Characterization of Fluid-Related Phenotypes in Pediatric Epilepsy: Deep Learning-Assisted Assessment of Enlarged Perivascular Space Burden, Regional Distribution, and Clinical Associations
    Adil Aytaç, Hilal Aydın
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. 89 Immunohistochemistry panel design with directly-conjugated antibodies for spatial characterization of the tumor immune microenvironment
    Kristina Hamilton, Jen Serafin, Mae Voeun
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. A glycolysis-associated four-gene risk model for prognosis and immune microenvironment characterization in hepatocellular carcinoma
    Shaohua Xu, Huiyao Xiang, Ming Xiang +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Proteomic Characterization of Prostate Cancer Bone Metastasis Subtypes Defines Progressive Remodeling States of the Bone-Tumor Microenvironment
    D. Xie, B. Mojtahedzahdeh, K. Chan +10
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  5. The loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma∗
    Olga Kersy, Nir Cohen, Mali Salmon-Divon +13
    Blood AdvancesPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
BibTeX
@misc{haselager2026singlecell,
  title = {{Single-cell characterization of 3D CLL spheroid model that recapitulates lymph node microenvironment-driven phenotypes and in vivo drug responses to ibrutinib}},
  author = {M. V. Haselager and D. Lashgari and A. Jongejan and J. L. Roos and M. Dijkema and J. Dubois and F. S. Peters and A. P. Kater and P. D. Moerland and E. Eldering},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.31.763314},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.31.763314v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Single-cell characterization of 3D CLL spheroid model that recapitulates lymph node microenvironment-driven phenotypes and in vivo drug responses to ibrutinib
AU  - M. V. Haselager
AU  - D. Lashgari
AU  - A. Jongejan
AU  - J. L. Roos
AU  - M. Dijkema
AU  - J. Dubois
AU  - F. S. Peters
AU  - A. P. Kater
AU  - P. D. Moerland
AU  - E. Eldering
PY  - 2026
DA  - 2026/10/31
PB  - bioRxiv
DO  - 10.64898/2026.10.31.763314
UR  - https://www.biorxiv.org/content/10.64898/2026.10.31.763314v1
AB  - Lymph node (LN) microenvironmental signals promote chronic lymphocytic leukemia (CLL) cell survival, proliferation, and treatment resistance. We previously developed a 3D culture model that recapitulates key features of this protective LN niche. Using single-cell RNA sequencing of ex vivo paired peripheral blood and LN samples, together with matched patient-derived CLL spheroids, we investigated how microenvironmental cues shape CLL phenotypes and their response to ibrutinib. A total of 3 functional CLL states (resting, activated, proliferating) were identified, with expanded populations of activated and proliferating subsets in 3D cultures. After 5 days of in vitro ibrutinib treatment, CLL cells shifted toward a resting phenotype, reflecting published responses in patients at 6 months. Activated CLL cells showed relative resistance to ibrutinib, associated with TLR9-MALT1-MYC pathway activation. The 3D model recapitulated tissue-specific T cell phenotypes observed in patients, and computational analyses predicted several T-to-CLL cell-mediated interactions supporting the LN niche. Collectively, these data reveal distinct ibrutinib responses among CLL subsets and establish the 3D model as a physiologically relevant platform.
ER  -